Summit tests Datroway+ivonescimab with AstraZeneca/Daiichi Sankyo in tumor types. Regeneron's ubamatamab shows 73% response ...
The Harvard lab of David Sinclair discusses a chemical cocktail it named SL-100 which, delivered in pill form, restored ...
Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic.
The Centers for Medicare and Medicaid Services finalized a demonstration program aimed at lowering the prices of ...
Parakeet Health raises a $10M Series A led by Canvas Ventures to expand AI patient outreach beyond dermatology.
Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess ...
A California biotech launched on Tuesday morning to try to bring a niche pain drug, approved in Italy for more than a decade, to the US. Investors are pumping $125 million into the company ...
Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data ...
Bristol Myers discloses a fatal liver injury in its Phase 3 program for pulmonary fibrosis drug admilparant ahead of a Q4 ...
ARCH and Population Health launch Somnivera with a $10.5M-upfront deal for an ex-China sleep drug from Jiangsu Nhwa.
Former House majority leader Eric Cantor has been chosen as PhRMA’s next CEO, according to two sources familiar ...
The cash should give the Stockholm-based biotech a runway “well into 2029,” CEO Patrik Strömberg told Endpoints News in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results